Trial Outcomes & Findings for Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism (NCT NCT04172441)

NCT ID: NCT04172441

Last Updated: 2025-03-14

Results Overview

Mean intravenous (IV) glucose infusion rate (GIR) in the last 12 hours of each treatment period during Part 1, the crossover part of the trial (dasiglucagon or placebo administration).

• Recruitment status: COMPLETED
• Study phase: PHASE2/PHASE3
• Target enrollment: 12 participants
• Primary outcome timeframe: Hours 36-48 after initiation of trial drug (Part 1)
• Results posted on: 2025-03-14

Participant Flow

Participant milestones

Measure	Dasiglucagon, Then Placebo Patients were treated with dasiglucagon for 48 hours in Part 1-1, then placebo for 48 hours in Part 1-2, and then dasiglucagon for 21 days in Part 2	Placebo, Then Dasiglucagon Patients were treated with placebo for 48 hours in Part 1-1, then dasiglucagon for 48 hours in Part 1-2, and then dasiglucagon for 21 days in Part 2
Part 1-1: First Intervention (48 Hours) STARTED	7	5
Part 1-1: First Intervention (48 Hours) COMPLETED	7	5
Part 1-1: First Intervention (48 Hours) NOT COMPLETED	0	0
Part 1-2: Second Intervention (48 Hours) STARTED	7	5
Part 1-2: Second Intervention (48 Hours) COMPLETED	7	5
Part 1-2: Second Intervention (48 Hours) NOT COMPLETED	0	0
Part 2: Open Label Dasiglucagon STARTED	7	5
Part 2: Open Label Dasiglucagon Completed Treatment	7	4
Part 2: Open Label Dasiglucagon COMPLETED	7	5
Part 2: Open Label Dasiglucagon NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Baseline characteristics by cohort

Measure	All Participants Who Received Treatment n=12 Participants All participants who received treatment
Age, Categorical <=18 years	12 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Age, Continuous	71.25 Days STANDARD_DEVIATION 84.976 • n=5 Participants
Sex: Female, Male Female	2 Participants n=5 Participants
Sex: Female, Male Male	10 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	11 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race/Ethnicity, Customized Race · Asian	2 Participants n=5 Participants
Race/Ethnicity, Customized Race · White	8 Participants n=5 Participants
Race/Ethnicity, Customized Race · Other	2 Participants n=5 Participants
Region of Enrollment United States	8 participants n=5 Participants
Region of Enrollment United Kingdom	3 participants n=5 Participants
Region of Enrollment Germany	1 participants n=5 Participants
Gastrostomy/nasogastric tube Gastrostomy	2 Participants n=5 Participants
Gastrostomy/nasogastric tube Nasogastric tube	7 Participants n=5 Participants
Gastrostomy/nasogastric tube None	3 Participants n=5 Participants

PRIMARY outcome

Timeframe: Hours 36-48 after initiation of trial drug (Part 1)

Mean intravenous (IV) glucose infusion rate (GIR) in the last 12 hours of each treatment period during Part 1, the crossover part of the trial (dasiglucagon or placebo administration).

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo n=12 Participants All patients treated with placebo in Part 1
Mean Intravenous Glucose Infusion Rate	4.33 mg/kg/minute Standard Deviation 4.922	9.51 mg/kg/minute Standard Deviation 5.655

SECONDARY outcome

Timeframe: 0 to 48 hours after initiation of trial drug

Total amount (g) of carbohydrates administered during the crossover part of the trial (dasiglucagon or placebo administration) per day.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo n=12 Participants All patients treated with placebo in Part 1
Carbohydrates Administered	106.7 g/day Standard Deviation 53.72	139.1 g/day Standard Deviation 57.35

SECONDARY outcome

Timeframe: 48 hours after initiation of trial drug (Part 1)

Mean IV GIR for each 48-hour treatment period during Part 1, the crossover part of the trial (dasiglucagon or placebo administration).

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo n=12 Participants All patients treated with placebo in Part 1
Mean Intravenous Glucose Infusion Rate	6.9 mg/kg/minute Standard Deviation 5.91	10.4 mg/kg/minute Standard Deviation 5.31

SECONDARY outcome

Timeframe: Hours 36-48 after initiation of trial drug (Part 1)

Mean IV GIR below 10 mg/kg/minute in the last 12 hours of each treatment period during Part 1, the crossover part of the trial (dasiglucagon or placebo administration) (yes/no)

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo n=12 Participants All patients treated with placebo in Part 1
Mean Intravenous Glucose Infusion Rate Below 10 mg/kg/Minute Mean IV GIR below 10 mg/kg/min in the last 12 hours of each treatment period during Part 1?: yes	9 Participants	6 Participants
Mean Intravenous Glucose Infusion Rate Below 10 mg/kg/Minute Mean IV GIR below 10 mg/kg/min in the last 12 hours of each treatment period during Part 1?: no	3 Participants	6 Participants

SECONDARY outcome

Timeframe: Days 5 to 25 (Part 2)

Time in days to complete weaning off IV glucose administration during Part 2, defined as the first point in time when the patient had been off IV glucose administration for at least 12 hours.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time to Complete Weaning Off Intravenous Glucose	5.8 days Interval 1.0 to 7.9	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Self-monitored plasma glucose episodes were set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Hypoglycemia event rate, defined as number of hypoglycemic events when PG was <70 mg/dL (or 3.9 mmol/L), as detected by self-monitored plasma glucose.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Hypoglycemia Event Rate in Part 2 Week 1 (Days 5 to 11)	8.50 episodes per week Interval 0.0 to 29.0	—
Hypoglycemia Event Rate in Part 2 Week 2 (Days 12 to 18)	6.0 episodes per week Interval 0.0 to 37.3	—
Hypoglycemia Event Rate in Part 2 Week 3 (Days 19 to 25)	3.79 episodes per week Interval 0.0 to 15.2	—
Hypoglycemia Event Rate in Part 2 Weeks 1 to 3 (Days 5 to 25)	6.04 episodes per week Interval 1.7 to 33.2	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Self-monitored plasma glucose episodes were set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Clinically significant hypoglycemia event rate, defined as number of events when PG was <54 mg/dL (3.0 mmol/L), as detected by self-monitored plasma glucose.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Clinically Significant Hypoglycemia Events in Part 2 Week 1 (Days 5 to 11)	1.67 episodes per week Interval 0.0 to 11.0	—
Clinically Significant Hypoglycemia Events in Part 2 Week 2 (Days 12 to 18)	1.00 episodes per week Interval 0.0 to 16.3	—
Clinically Significant Hypoglycemia Events in Part 2 Week 3 (Days 19 to 25)	2.92 episodes per week Interval 0.0 to 4.0	—
Clinically Significant Hypoglycemia Events in Part 2 Weeks 1 to 3 (Days 5 to 25)	1.67 episodes per week Interval 0.3 to 13.7	—

SECONDARY outcome

Timeframe: Days 5 to 25

Time in days to actual hospital discharge defined as the time from first exposure to the study drug in Part 2 to discharge from hospital.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time to Actual Hospital Discharge	NA days Interval 11.7 to A median value and upper limit of the 95% confidence interval were not calculable due to an insufficient number of patients being discharged from hospital.	—

SECONDARY outcome

Timeframe: Days 5 to 25

Time (days) to pancreatic surgery (sub-total or total pancreatectomy with a cutoff of ≥95%).

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time to Pancreatic Surgery	NA days The median value and 95% confidence interval were not calculable due to an insufficient number of patients undergoing sub-total or total pancreatectomy with a cutoff of ≥95%.	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Carbohydrates amount administered was set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Total amount (g) of carbohydrates administered (regardless of the route) per day.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Carbohydrates Administered Week 1 (Days 5 to 11)	91.03 g/day Interval 57.6 to 190.8	—
Carbohydrates Administered Week 2 (Days 12 to 18)	75.09 g/day Interval 29.8 to 218.3	—
Carbohydrates Administered Week 3 (Days 19 to 25)	80.73 g/day Interval 0.0 to 222.1	—
Carbohydrates Administered Weeks 1 to 3 (Days 5 to 25)	87.37 g/day Interval 39.5 to 195.9	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Carbohydrates amount administered was set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Amount (g) of carbohydrates administered via IV glucose infusion or bolus or total parenteral nutrition. This secondary endpoint was intended to account only for carbohydrates administered via IV glucose infusion or bolus. It was not possible to differentiate between carbohydrates administered via IV glucose infusion or bolus and carbohydrates administered as being, or not being, part of total parenteral nutrition from the collected data. This endpoint was expanded to include both.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Carbohydrates Administered Intravenously Week 1 (Days 5 to 11)	41.35 g/day Interval 3.6 to 118.8	—
Carbohydrates Administered Intravenously Week 2 (Days 12 to 18)	2.12 g/day Interval 0.0 to 82.2	—
Carbohydrates Administered Intravenously Week 3 (Days 19 to 25)	0.35 g/day Interval 0.0 to 119.0	—
Carbohydrates Administered Intravenously Weeks 1 to 3 (Days 5 to 25)	22.60 g/day Interval 1.2 to 88.5	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: It was not possible to differentiate between carbohydrates administered via IV glucose infusion or bolus and carbohydrates administered as being, or not being, part of total parenteral nutrition because some of the carbohydrates that were given as a part of parenteral nutrition were also reported as carbohydrates administered intravenously. All available results regarding administration of carbohydrates are presented in outcome measure 11.

Amount (g) of carbohydrates administered as part of total parenteral nutrition.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Carbohydrates amount administered was set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Amount (g) of carbohydrates administered via oral route.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Carbohydrates Administered Orally Week 1 (Days 5 to 11)	19.57 g/day Interval 0.0 to 67.5	—
Carbohydrates Administered Orally Week 2 (Days 12 to 18)	0.37 g/day Interval 0.0 to 88.9	—
Carbohydrates Administered Orally Week 3 (Days 19 to 25)	0.23 g/day Interval 0.0 to 53.8	—
Carbohydrates Administered Orally Weeks 1 to 3 (Days 5 to 25)	13.38 g/day Interval 0.0 to 63.4	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Carbohydrates amount administered was set to missing after pancreatectomy; 2 patients had near-total or partial pancreatectomies during Part 2 of the study.

Amount (g) of carbohydrates administered via nasogastric tube or gastrostomy.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Carbohydrates Administered Via Gastric Feed Week 1 (Days 5 to 11)	34.43 g/day Interval 0.0 to 88.7	—
Carbohydrates Administered Via Gastric Feed Week 2 (Days 12 to 18)	52.87 g/day Interval 9.0 to 92.8	—
Carbohydrates Administered Via Gastric Feed Week 3 (Days 19 to 25)	57.90 g/day Interval 0.0 to 76.1	—
Carbohydrates Administered Via Gastric Feed Weeks 1 to 3 (Days 5 to 25)	43.96 g/day Interval 0.0 to 85.0	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Percent time in range (PG between 70 to 180 mg/dL [3.9-10.0 mmol/L]) as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time in Range in Part 2 Week 1 (Days 5 to 11)	86.69 percent time Interval 34.5 to 94.3	—
Time in Range in Part 2 Week 2 (Days 12 to 18)	87.87 percent time Interval 51.0 to 95.9	—
Time in Range in Part 2 Week 3 (Days 19 to 25)	91.42 percent time Interval 36.3 to 100.0	—
Time in Range in Part 2 Weeks 1 to 3 (Days 5 to 25)	88.35 percent time Interval 42.5 to 100.0	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Percent time in hypoglycemia (when PG was <70 mg/dL [or 3.9 mmol/L]) as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time in Hypoglycemia in Part 2 Week 1 (Days 5 to 11)	7.20 percent time Interval 1.0 to 24.5	—
Time in Hypoglycemia in Part 2 Week 2 (Days 12 to 18)	8.82 percent time Interval 0.6 to 49.0	—
Time in Hypoglycemia in Part 2 Week 3 (Days 19 to 25)	5.73 percent time Interval 0.0 to 22.1	—
Time in Hypoglycemia in Part 2 Weeks 1 to 3 (Days 5 to 25)	6.67 percent time Interval 0.0 to 30.0	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Percent time in clinically significant hypoglycemia (when PG was <54 mg/dL [or 3.0 mmol/L]) as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time in Clinically Significant Hypoglycemia in Part 2 Week 1 (Days 5 to 11)	2.07 percent time Interval 0.2 to 6.0	—
Time in Clinically Significant Hypoglycemia in Part 2 Week 2 (Days 12 to 18)	2.20 percent time Interval 0.0 to 20.4	—
Time in Clinically Significant Hypoglycemia in Part 2 Week 3 (Days 19 to 25)	0.88 percent time Interval 0.0 to 6.8	—
Time in Clinically Significant Hypoglycemia in Part 2 Weeks 1 to 3 (Days 5 to 25)	1.75 percent time Interval 0.0 to 9.2	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Rate of hypoglycemia episodes, defined as number of episodes per week when PG was <70 mg/dL (3.9 mmol/L) for 15 minutes or more, as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Hypoglycemia Episodes in Part 2 Week 1 (Days 5 to 11)	25.00 episodes per week Interval 3.0 to 58.0	—
Hypoglycemia Episodes in Part 2 Week 2 (Days 12 to 18)	26.50 episodes per week Interval 3.0 to 74.7	—
Hypoglycemia Episodes in Part 2 Week 3 (Days 19 to 25)	18.63 episodes per week Interval 0.0 to 58.3	—
Hypoglycemia Episodes in Part 2 Weeks 1 to 3 (Days 5 to 25)	18.54 episodes per week Interval 0.0 to 66.3	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Rate of clinically significant hypoglycemia episodes, defined as number of episodes per week when was <54 mg/dL (3.0 mmol/L) for 15 minutes or more, as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Clinically Significant Hypoglycemia Episodes in Part 2 Week 1 (Days 5 to 11)	5.00 episodes per week Interval 1.0 to 23.0	—
Clinically Significant Hypoglycemia Episodes in Part 2 Week 2 (Days 12 to 18)	8.50 episodes per week Interval 0.0 to 46.7	—
Clinically Significant Hypoglycemia Episodes in Part 2 Week 3 (Days 19 to 25)	2.67 episodes per week Interval 0.0 to 18.7	—
Clinically Significant Hypoglycemia Episodes in Part 2 Weeks 1 to 3 (Days 5 to 25)	5.00 episodes per week Interval 0.0 to 34.8	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Extent of hypoglycemia (defined as the area over the glucose curve [AOCglucose] below 70 mg/dL [3.9 mmol/L]) as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Extent of Hypoglycemia in Part 2 Week 1 (Days 5 to 11)	0.87 mg/dL/hour Interval 0.1 to 2.7	—
Extent of Hypoglycemia in Part 2 Week 2 (Days 12 to 18)	0.97 mg/dL/hour Interval 0.0 to 8.9	—
Extent of Hypoglycemia in Part 2 Week 3 (Days 19 to 25)	0.59 mg/dL/hour Interval 0.1 to 2.6	—
Extent of Hypoglycemia in Part 2 Weeks 1 to 3 (Days 5 to 25)	0.89 mg/dL/hour Interval 0.1 to 4.3	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients during all weeks.

Extent of clinically significant hypoglycemia (defined as the area over the glucose curve [AOCglucose] below 54 mg/dL [3.0 mmol/L]) as measured by continuous glucose monitoring, divided by the total duration in hours of continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Extent of Clinically Significant Hypoglycemia in Part 2 Week 1 (Days 5 to 11)	0.14 mg/dL/hour Interval 0.0 to 0.4	—
Extent of Clinically Significant Hypoglycemia in Part 2 Week 2 (Days 12 to 18)	0.13 mg/dL/hour Interval 0.0 to 2.1	—
Extent of Clinically Significant Hypoglycemia in Part 2 Week 3 (Days 19 to 25)	0.12 mg/dL/hour Interval 0.0 to 0.4	—
Extent of Clinically Significant Hypoglycemia in Part 2 Weeks 1 to 3 (Days 5 to 25)	0.14 mg/dL/hour Interval 0.0 to 0.8	—

SECONDARY outcome

Timeframe: Days 5 to 25

Population: Data were not available from all patients from all weeks.

Percent time in hyperglycemia (when PG was >180 mg/dL [10.0 mmol/L]), as measured by continuous glucose monitoring.

Outcome measures

Measure	Dasiglucagon n=12 Participants All patients treated with dasiglucagon in Part 1	Placebo All patients treated with placebo in Part 1
Time in Hyperglycemia in Part 2 Week 1 (Days 5 to 11)	1.74 percent time Interval 0.0 to 64.5	—
Time in Hyperglycemia in Part 2 Week 2 (Days 12 to 18)	0.81 percent time Interval 0.0 to 45.0	—
Time in Hyperglycemia in Part 2 Week 3 (Days 19 to 25)	0.32 percent time Interval 0.0 to 62.7	—
Time in Hyperglycemia in Part 2 Weeks 1 to 3 (Days 5 to 25)	1.48 percent time Interval 0.0 to 56.6	—

Adverse Events

Part 1: Dasiglucagon

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Part 1: Placebo

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

Part 2: Dasiglucagon

Serious events: 1 serious events

Other events: 10 other events

Deaths: 0 deaths

Parts 1 and 2: Dasiglucagon

Serious events: 1 serious events

Other events: 10 other events

Deaths: 0 deaths

Follow-up Period

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Measure	Part 1: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Part 1 of the study.	Part 1: Placebo n=12 participants at risk Adverse events during administration of placebo during Part 1 of the study.	Part 2: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Part 2 of the study.	Parts 1 and 2: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Parts 1 and 2 of the study.	Follow-up Period n=1 participants at risk Adverse events occurring during the Follow-up Period.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.

Other adverse events

Measure	Part 1: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Part 1 of the study.	Part 1: Placebo n=12 participants at risk Adverse events during administration of placebo during Part 1 of the study.	Part 2: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Part 2 of the study.	Parts 1 and 2: Dasiglucagon n=12 participants at risk Adverse events during administration of dasiglucagon during Parts 1 and 2 of the study.	Follow-up Period n=1 participants at risk Adverse events occurring during the Follow-up Period.
Cardiac disorders Tachycardia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Respiratory, thoracic and mediastinal disorders Tachypnoea	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Respiratory, thoracic and mediastinal disorders Respiratory Distress	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Respiratory, thoracic and mediastinal disorders Pulmonary Oedema	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Gastrointestinal disorders Vomiting	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	25.0% 3/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Gastrointestinal disorders Constipation	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	100.0% 1/1 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Gastrointestinal disorders Gastrooesophageal Reflux Disease	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Gastrointestinal disorders Diarrhoea	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Gastrointestinal disorders Haematochezia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Investigations Aspartate Aminotransferase Increased	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Investigations Alanine Aminotransferase Increased	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Musculoskeletal and connective tissue disorders Finger Deformity	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Rash	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Rash Papular	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	25.0% 3/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	25.0% 3/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Dermatitis Diaper	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Acne Infantile	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Dermatitis Contact	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Rash Maculo-Papular	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Seborrhoeic Dermatitis	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Skin and subcutaneous tissue disorders Sensitive Skin	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	100.0% 1/1 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 3 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 4 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 4 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Acidosis Hyperchloraemic	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Fluid Retention	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Hypochloraemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
General disorders Pyrexia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	16.7% 2/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
General disorders Face Oedema	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
General disorders Medical Device Site Reaction	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Vascular disorders Thrombophlebitis Superficial	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Blood and lymphatic system disorders Anaemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	25.0% 3/12 • Number of events 4 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	25.0% 3/12 • Number of events 4 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Blood and lymphatic system disorders Normocytic Anaemia	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Device Related Sepsis	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Eye Infection	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Fungal Skin Infection	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 2 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Oral Candidiasis	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Parainfluenzae Virus Infection	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Infections and infestations Rash Pustular	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Eye disorders Dry Eye	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Injury, poisoning and procedural complications Procedural Pain	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Haemangioma Of Liver	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.
Product Issues Device Occlusion	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/12 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	8.3% 1/12 • Number of events 1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.	0.00% 0/1 • Treatment-emergent adverse events are reported here, and were recorded from the time of first administration of study treatment until the end of the posttreatment follow-up period or inclusion in the ZP4207-17106 extension trial (up to 8 weeks, from Day 1 through Day 56). Note that the reporting groups are not mutually exclusive.

Additional Information

Charlotte Teglman Schiøler

Zealand Pharma A/S

Phone: +45 5060 3722

Email: cschioler@zealandpharma.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place